Pamela Watson
Family · Suwanee, GANPI 1225183163
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 466 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,068 and has fallen 77.4% since, to $468 in 2025. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$904
- Esperion Therapeutics, Inc.$497
- AbbVie$486
- GSK$426
- Bayer$409
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,056100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 87 | $1,079 |
| Amgen | 44 | $904 |
| Esperion Therapeutics, Inc. | 23 | $497 |
| AbbVie | 31 | $486 |
| GSK | 14 | $426 |
| Bayer | 17 | $409 |
| AstraZeneca | 22 | $361 |
| Kowa Pharmaceuticals America, Inc. | 83 | $345 |
| Lilly USA, LLC | 17 | $309 |
| Novartis | 24 | $295 |
| Noven Therapeutics, LLC | 13 | $255 |
| Pfizer | 9 | $196 |
| Exact Sciences | 9 | $170 |
| Eisai Inc. | 6 | $163 |
| Amarin Pharma, Inc. | 10 | $155 |
| Johnson & Johnson | 7 | $126 |
| Sanofi-aventis U.S. LLC | 6 | $121 |
| Teva Pharmaceuticals USA, Inc. | 8 | $118 |
| Abbott | 5 | $97 |
| Boehringer Ingelheim | 6 | $80 |
| Jazz Pharmaceuticals Inc. | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Astellas Pharma US Inc | 3 | $49 |
| Philips North America LLC | 2 | $42 |
| Dexcom, Inc. | 2 | $39 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Merck | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Bausch Health US, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,056 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $82,978 |
| JanuviaSitagliptin Phosphate | 26 | $35,572 |
| FarxigaDapagliflozin Propanediol | 23 | $31,123 |
| JardianceEmpagliflozin | 24 | $27,408 |
| MounjaroTirzepatide | 26 | $27,284 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $25,366 |
| EliquisApixaban | 25 | $24,019 |
| MyrbetriqMirabegron | 14 | $17,511 |
| XareltoRivaroxaban | 17 | $14,469 |
| Repatha SureclickEvolocumab | 12 | $12,314 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $7,285 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,004 |
| LinzessLinaclotide | 13 | $6,817 |
| Colesevelam Hcl | 18 | $5,801 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $4,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,079 | $82,97852 claims |
| MerckJanuvia | $36 | $35,57226 claims |
| AstraZenecaFarxiga, Symbicort | $361 | $34,51535 claims |
| Boehringer IngelheimJardiance | $80 | $27,40824 claims |
| Lilly USA, LLCMounjaro | $309 | $27,28426 claims |
| GSKTrelegy Ellipta | $426 | $25,36619 claims |
| PfizerEliquis | $196 | $24,01925 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $17,51114 claims |
| Johnson & JohnsonXarelto | $126 | $14,46917 claims |
| AbbVieLinzess, Synthroid | $486 | $10,44056 claims |
| Esperion Therapeutics, Inc.Nexlizet | $497 | $7,28511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Suwanee
- Blair LinsleySuwanee$22K
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.